LimmaTech Biologics AG
LimmaTech Biologics AG is a Swiss clinical-stage biotech company based in Schlieren developing next-generation vaccines against multidrug-resistant bacterial infections and other severe diseases caused by microbial pathogens. Eli Lilly acquired the company in 2026 for up to $780 million.
Schlieren · 1+ investments · 1 portfolio companies
- Headquarters
- Schlieren
- Founded
- 2015
- Website
- lmtbio.com
- Portfolio Company
- 1
- Total Investment
- 1
- Last Investment
- Nov 2021
Overview
LimmaTech Biologics AG is a Venture Capital firm based in Schlieren. It has made 1 investment, including GlycoEra.
Portfolio1
Co-investors6
Sign up to view co-investors
6 co-investors across 6 shared portfolio companies — who they back alongside, and how often they lead.
Venture Capital ×6 · 3 shared rounds
Investment History
Sign up to view investment history
Create a free account with 25 free credits every month, no card needed, to unlock deal history, amounts, and round details.
Your firm? Embed this profile
Add the live badge to your site — it stays current as your portfolio data updates.
<a href="https://indexed.vc/investors/limmatech-biologics-ag"><img src="https://indexed.vc/api/badge/investor/limmatech-biologics-ag" alt="LimmaTech Biologics AG on Indexed.vc" width="260" height="76" /></a>